TY - JOUR
T1 - Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma
AU - Alam, R
AU - Rezaee, ME
AU - Pallauf, M
AU - Elias, R
AU - Yerrapragada, A
AU - Enikeev, D
AU - Fang, D
AU - Shariat, SF
AU - Woldu, SL
AU - Ged, YMA
AU - Singla, N
N1 - Pallauf: Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria
PY - 2023
Y1 - 2023
N2 - Purpose: Racially driven outcomes in cancer are challenging to study. Studies evaluating the impact of race in renal cell carcinoma (RCC) outcomes are inconsistent and unable to disentangle socioeconomic disparities from inherent biological differences. We therefore seek to investigate socioeconomic determinants of racial disparities with respect to overall survival (OS) when comparing Black and White patients with RCC.Methods: We queried the National Cancer Database (NCDB) for patients diagnosed with RCC between 2004 and 2017 with complete clinicodemographic data. Patients were examined across various stages (all, cT1aN0M0, and cM1) and subtypes (all, clear cell, or papillary). We performed Cox proportional hazards regression with adjustment for socioeconomic and disease factors.Results: There were 386,589 patients with RCC, of whom 46,507 (12.0%) were Black. Black patients were generally younger, had more comorbid conditions, less likely to be insured, in a lower income quartile, had lower rates of high school completion, were more likely to have papillary RCC histology, and more likely to be diagnosed at a lower stage of RCC than their white counterparts. By stage, Black patients demonstrated a 16% (any stage), 22.5% (small renal mass [SRM]), and 15% (metastatic) higher risk of mortality than White patients. Survival differences were also evident in histology-specific subanalyses. Socioeconomic factors played a larger role in predicting OS among patients with SRMs than in patients with metastasis.Conclusions: Black patients with RCC demonstrate worse survival outcomes compared to White patients across all stages. Socioeconomic disparities between races play a significant role in influencing survival in RCC. (c) 2023 Elsevier Inc. All rights reserved.
AB - Purpose: Racially driven outcomes in cancer are challenging to study. Studies evaluating the impact of race in renal cell carcinoma (RCC) outcomes are inconsistent and unable to disentangle socioeconomic disparities from inherent biological differences. We therefore seek to investigate socioeconomic determinants of racial disparities with respect to overall survival (OS) when comparing Black and White patients with RCC.Methods: We queried the National Cancer Database (NCDB) for patients diagnosed with RCC between 2004 and 2017 with complete clinicodemographic data. Patients were examined across various stages (all, cT1aN0M0, and cM1) and subtypes (all, clear cell, or papillary). We performed Cox proportional hazards regression with adjustment for socioeconomic and disease factors.Results: There were 386,589 patients with RCC, of whom 46,507 (12.0%) were Black. Black patients were generally younger, had more comorbid conditions, less likely to be insured, in a lower income quartile, had lower rates of high school completion, were more likely to have papillary RCC histology, and more likely to be diagnosed at a lower stage of RCC than their white counterparts. By stage, Black patients demonstrated a 16% (any stage), 22.5% (small renal mass [SRM]), and 15% (metastatic) higher risk of mortality than White patients. Survival differences were also evident in histology-specific subanalyses. Socioeconomic factors played a larger role in predicting OS among patients with SRMs than in patients with metastasis.Conclusions: Black patients with RCC demonstrate worse survival outcomes compared to White patients across all stages. Socioeconomic disparities between races play a significant role in influencing survival in RCC. (c) 2023 Elsevier Inc. All rights reserved.
KW - Race
KW - Socioeconomics
KW - Renal cell carcinoma
KW - Survival
KW - HISTOLOGIC SUBTYPE
KW - CANCER
KW - PAPILLARY
KW - RACE
U2 - 10.1016/j.urolonc.2023.08.016
DO - 10.1016/j.urolonc.2023.08.016
M3 - Original Article
C2 - 37709565
SN - 1078-4139
VL - 41
JO - UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS
JF - UROLOGIC ONCOLOGY - SEMINARS AND ORIGINAL INVESTIGATIONS
IS - 11
ER -